TY - JOUR
T1 - The mid-term effect of Osgood-Schlatter disease on knee function in young players from elite soccer academies
AU - Bezuglov, E.
AU - Pirmakhanov, B.
AU - Ussatayeva, G.
AU - Emanov, A.
AU - Valova, Yu
AU - Kletsovskiy, A.
AU - Khaitin, V.
AU - Usmanova, E.
AU - Butovskiy, M.
AU - Morgans, R.
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022/11/22
Y1 - 2022/11/22
N2 - Background: The aim of the study was to evaluate the effect of Osgood-Schlatter disease (OSD) on knee joint function in elite young soccer players. Our hypothesis was that knee joint function in elite young soccer players was impaired following OSD compared with soccer players with no history of OSD. Method: In young male soccer players (n = 36) from elite academies (mean ±SD, age: age: 15,3 ± 1,7 years; height: 1,7 ± 0,06 m; weight: 63,5 ± 8 kg; BMI: 20,7 ± 2). The duration between the completion of treatment or the last complaint to the study commencement was 31 ± 19 months. Results: The average treatment duration of OSD among study participants was 18,5 ± 12 days (95%, 14–23), and the disease most often manifested in winter and spring, 33% and 31% of cases, respectively. Soccer players with a history of OSD were statistically different in IKDC and KOOS scores when compared with soccer players with no previously reported OSD (Mann-Whitney, p < 0,0001). The soccer players with a history of OSD also use NSAIDs more frequently compared with soccer players with no history of OSD (36% vs 3% respectively). Conclusions: OSD among young soccer players, when symptoms resolve, continue about one month and they can return to regular training and participation in games. Wherein, the negative effects in knee joint function were significantly more likely in soccer players with previous OSD history when compared with their peers with no history of OSD. While oral non-steroidal anti-inflammatory drugs was also more widely employed in soccer players with previous OSD history. Potentially this may lead to performance deficits and disadvantages for their future careers and coaches and physicians should be informed.
AB - Background: The aim of the study was to evaluate the effect of Osgood-Schlatter disease (OSD) on knee joint function in elite young soccer players. Our hypothesis was that knee joint function in elite young soccer players was impaired following OSD compared with soccer players with no history of OSD. Method: In young male soccer players (n = 36) from elite academies (mean ±SD, age: age: 15,3 ± 1,7 years; height: 1,7 ± 0,06 m; weight: 63,5 ± 8 kg; BMI: 20,7 ± 2). The duration between the completion of treatment or the last complaint to the study commencement was 31 ± 19 months. Results: The average treatment duration of OSD among study participants was 18,5 ± 12 days (95%, 14–23), and the disease most often manifested in winter and spring, 33% and 31% of cases, respectively. Soccer players with a history of OSD were statistically different in IKDC and KOOS scores when compared with soccer players with no previously reported OSD (Mann-Whitney, p < 0,0001). The soccer players with a history of OSD also use NSAIDs more frequently compared with soccer players with no history of OSD (36% vs 3% respectively). Conclusions: OSD among young soccer players, when symptoms resolve, continue about one month and they can return to regular training and participation in games. Wherein, the negative effects in knee joint function were significantly more likely in soccer players with previous OSD history when compared with their peers with no history of OSD. While oral non-steroidal anti-inflammatory drugs was also more widely employed in soccer players with previous OSD history. Potentially this may lead to performance deficits and disadvantages for their future careers and coaches and physicians should be informed.
KW - IKDC
KW - KOOS
KW - Osgood-Schlatter disease
KW - elite young soccer players
KW - tibial tuberosity apophysitis
UR - http://www.scopus.com/inward/record.url?scp=85142421443&partnerID=8YFLogxK
U2 - 10.1080/00913847.2022.2148492
DO - 10.1080/00913847.2022.2148492
M3 - Article
C2 - 36413052
AN - SCOPUS:85142421443
SN - 0091-3847
VL - 51
SP - 590
EP - 595
JO - Physician and Sportsmedicine
JF - Physician and Sportsmedicine
IS - 6
ER -